QQQ   415.94 (-1.76%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
QQQ   415.94 (-1.76%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
QQQ   415.94 (-1.76%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
QQQ   415.94 (-1.76%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioForce Nanosciences Holdings, Inc. stock logo
BFNH
BioForce Nanosciences
$1.74
-0.6%
$1.76
$0.95
$2.75
N/A-1.651,114 shs367 shs
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$0.76
-3.3%
$1.10
$0.71
$8.20
$41.63M2.331.67 million shs499,689 shs
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$17.40
-0.6%
$23.91
$5.32
$30.99
$867.06M1.64988,106 shs1.06 million shs
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
$6.00
$3.50
$7.95
N/A0.99294,806 shs773,040 shs
Precipio, Inc. stock logo
PRPO
Precipio
$6.20
-7.6%
$6.41
$4.75
$14.80
$8.87M1.616,366 shs1,612 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioForce Nanosciences Holdings, Inc. stock logo
BFNH
BioForce Nanosciences
-0.57%+2.35%-2.25%-6.45%+72.28%
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-3.51%-23.57%-24.31%-37.02%-89.29%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-16.43%-23.55%-20.81%-21.59%+224.68%
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
0.00%0.00%0.00%0.00%-84.76%
Precipio, Inc. stock logo
PRPO
Precipio
0.00%+0.86%+7.28%-2.69%-50.14%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioForce Nanosciences Holdings, Inc. stock logo
BFNH
BioForce Nanosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
1.7963 of 5 stars
3.33.00.00.02.00.01.3
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
1.7752 of 5 stars
3.51.00.00.02.63.30.0
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
0.3361 of 5 stars
2.03.00.00.00.00.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioForce Nanosciences Holdings, Inc. stock logo
BFNH
BioForce Nanosciences
N/AN/AN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
2.67
Moderate Buy$21.332,702.96% Upside
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
3.00
Buy$33.8694.58% Upside
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
N/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
N/AN/A$40.00545.16% Upside

Current Analyst Ratings

Latest EYPT, BNGO, PRPO, HTGM, and BFNH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/7/2024
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$7.00 ➝ $6.00
2/16/2024
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
2/16/2024
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$30.00 ➝ $39.00
1/22/2024
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$35.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioForce Nanosciences Holdings, Inc. stock logo
BFNH
BioForce Nanosciences
N/AN/AN/AN/AN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$36.12M1.15N/AN/A$2.10 per share0.36
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$46.02M18.84N/AN/A$5.66 per share3.07
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
$6.37M0.00N/AN/A$2.44 per share0.00
Precipio, Inc. stock logo
PRPO
Precipio
$15.20M0.58N/AN/A$10.16 per share0.61

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioForce Nanosciences Holdings, Inc. stock logo
BFNH
BioForce Nanosciences
-$470K-$0.01N/AN/AN/AN/A-70,870.86%5/7/2024 (Estimated)
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$232.49M-$6.62N/AN/AN/A-643.74%-103.68%-71.45%5/14/2024 (Estimated)
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$70.79M-$1.83N/AN/AN/A-153.84%-61.48%-33.49%5/1/2024 (Estimated)
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
-$21.59MN/A0.00N/AN/A-324.25%45.52%8.93%N/A
Precipio, Inc. stock logo
PRPO
Precipio
-$5.85M-$4.56N/AN/A-38.51%-51.75%-37.93%5/10/2024 (Estimated)

Latest EYPT, BNGO, PRPO, HTGM, and BFNH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/1/2024Q4 2023
BioForce Nanosciences Holdings, Inc. stock logo
BFNH
BioForce Nanosciences
N/A-$0.01-$0.01-$0.01N/AN/A
3/7/202412/31/2023
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$0.60-$0.33+$0.27-$0.33$8.71 million$14.03 million  
3/5/2024Q4 2023
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
N/A-$0.96-$0.96-$0.96N/A$10.72 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioForce Nanosciences Holdings, Inc. stock logo
BFNH
BioForce Nanosciences
N/AN/AN/AN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
N/AN/AN/AN/AN/A
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/AN/AN/AN/AN/A
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
N/AN/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioForce Nanosciences Holdings, Inc. stock logo
BFNH
BioForce Nanosciences
N/AN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
0.04
1.40
1.17
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/A
5.45
5.39
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
N/A
1.40
1.30
Precipio, Inc. stock logo
PRPO
Precipio
0.01
1.17
1.05

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BioForce Nanosciences Holdings, Inc. stock logo
BFNH
BioForce Nanosciences
3N/AN/ANot Optionable
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
34454.69 million53.36 millionOptionable
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
12149.83 million43.33 millionOptionable
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
842.21 million2.16 millionOptionable
Precipio, Inc. stock logo
PRPO
Precipio
511.43 million1.28 millionOptionable

EYPT, BNGO, PRPO, HTGM, and BFNH Headlines

SourceHeadline
Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200-Day Moving Average of $6.62Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200-Day Moving Average of $6.62
americanbankingnews.com - April 16 at 3:36 AM
Precipio Announces Year end 2023 Shareholder Update CallPrecipio Announces Year end 2023 Shareholder Update Call
globenewswire.com - March 25 at 5:00 PM
Precipio, Inc. (PRPO)Precipio, Inc. (PRPO)
ca.finance.yahoo.com - March 12 at 9:50 AM
Precipio Stock (NASDAQ:PRPO), Analyst Ratings, Price Targets, PredictionsPrecipio Stock (NASDAQ:PRPO), Analyst Ratings, Price Targets, Predictions
benzinga.com - February 23 at 5:33 AM
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoYPrecipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
finance.yahoo.com - February 13 at 5:30 PM
Precipio, Inc.: Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen Portfolio of Molecular assays for CancerPrecipio, Inc.: Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen Portfolio of Molecular assays for Cancer
finanznachrichten.de - February 6 at 4:00 PM
Precipio’s Q4 cash burn from operations drops below $100K for full quarterPrecipio’s Q4 cash burn from operations drops below $100K for full quarter
msn.com - January 23 at 4:19 PM
Precipio, Inc.: Precipios Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterPrecipio, Inc.: Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
finanznachrichten.de - January 23 at 4:19 PM
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterPrecipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
finance.yahoo.com - January 23 at 4:19 PM
Precipio, Inc.: Precipio Signs Distribution Agreement For IV-Cell and HemeScreen in JapanPrecipio, Inc.: Precipio Signs Distribution Agreement For IV-Cell and HemeScreen in Japan
finanznachrichten.de - January 17 at 3:59 PM
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in JapanPrecipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
finance.yahoo.com - January 17 at 3:59 PM
Precipio Announces Christina Valauri joins the Board of DirectorsPrecipio Announces Christina Valauri joins the Board of Directors
finance.yahoo.com - January 2 at 9:25 AM
Precipio, Inc.: Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024Precipio, Inc.: Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
finanznachrichten.de - December 15 at 8:20 AM
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
finance.yahoo.com - December 14 at 7:47 PM
Precipio: Regulation Fd Disclosure, Financial Statements And ExhibitsPrecipio: Regulation Fd Disclosure, Financial Statements And Exhibits
cbonds.com - November 18 at 7:00 AM
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
finance.yahoo.com - October 18 at 9:36 AM
Precipio, Inc.: Precipios Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023Precipio, Inc.: Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
finanznachrichten.de - October 3 at 1:42 PM
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
finance.yahoo.com - October 3 at 1:42 PM
Precipio Continues to Sign New HemeScreen™ CustomersPrecipio Continues to Sign New HemeScreen™ Customers
finance.yahoo.com - September 28 at 2:36 PM
Precipio Reduces Product Revenue Result Needed for Cash Flow BreakevenPrecipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
finance.yahoo.com - September 25 at 3:15 PM
Precipio, Inc.: Precipio Takes Final Step Towards Regaining Nasdaq CompliancePrecipio, Inc.: Precipio Takes Final Step Towards Regaining Nasdaq Compliance
finanznachrichten.de - September 22 at 10:32 AM
Precipio (NASDAQ: PRPO) to jump 2,000% at the open - nominal price change, technicalPrecipio (NASDAQ: PRPO) to jump 2,000% at the open - nominal price change, technical
dhakatribune.com - September 22 at 10:32 AM
Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of PlanPrecipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
finance.yahoo.com - September 13 at 7:15 PM
Broker Revenue Forecasts For Precipio, Inc. (NASDAQ:PRPO) Are Surging HigherBroker Revenue Forecasts For Precipio, Inc. (NASDAQ:PRPO) Are Surging Higher
finance.yahoo.com - August 20 at 5:26 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BioForce Nanosciences logo

BioForce Nanosciences

OTCMKTS:BFNH
BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online under the BioForce Eclipse brand, as well as through social media and telemarketing. BioForce Nanosciences Holdings, Inc. was incorporated in 1999 and is based in Virginia Beach, Virginia.
Bionano Genomics logo

Bionano Genomics

NASDAQ:BNGO
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
EyePoint Pharmaceuticals logo

EyePoint Pharmaceuticals

NASDAQ:EYPT
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
HTG Molecular Diagnostics logo

HTG Molecular Diagnostics

NASDAQ:HTGM
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
Precipio logo

Precipio

NASDAQ:PRPO
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.